PRN Company Report

Analyst Coverage

Research analysts covering PRN.

Recent press releases and 8-K filings for PRN.

Profound Medical Reports Strong Q3 2025 Revenue Growth and Product Launch

PRN

Earnings

Product Launch

Revenue Acceleration/Inflection

Profound Medical reported Q3 2025 revenue of $5.3 million, an 87% increase from $2.8 million in Q3 2024, with $4.1 million from recurring revenue and $1.2 million from one-time capital equipment sales.
The company achieved a gross margin of 74.3% in Q3 2025, compared to 63.1% in Q3 2024, and recorded a net loss of $8 million or $0.26 per common share, an improvement from a net loss of $9.4 million or $0.38 per common share in Q3 2024.
As of September 30, 2025, Profound had $24.8 million in cash and expects to achieve profitable growth and become cash flow positive as revenue grows and margins remain high.
The full product release of the new TULSA AI Volume Reduction Software for BPH treatment will launch at RSNA at the end of November, with the potential to add 400,000 patients to the annual Total Addressable Market, essentially tripling the previous TAM.
The TULSA-PRO install base reached 70 sites as of the call date, with a sales pipeline of 93 new systems in the final stages of the sales process, and the company remains comfortable with a 70% growth target for the year.

Nov 13, 2025, 9:30 PM

Profound Medical Reports Strong Q3 Growth and Outlines Future Expansion Plans

PRN

Revenue Acceleration/Inflection

Product Launch

New Projects/Investments

Profound Medical pre-announced 85% revenue growth in the third quarter and expanded its TULSA PRO installed base to 67 sites, with a target of 75 sites by year-end.
The company is experiencing increased adoption of its TULSA PRO system due to Medicare reimbursement being in place, which has led to hospitals seeing profitability and increased interest across various customer segments.
A full launch of the BPH software is expected in the next four weeks, which will significantly increase the total addressable market and scheduling flexibility for physicians. The company also has a strong pipeline of potential sites in the advanced stages of its sales process.
Management is confident about 2026 revenue projections (analyst projection of $32 million, consensus $36 million) and aims to reach 200 TULSA PRO sites in the short term, which could generate approximately $55 million in recurring revenue annually.